• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott launches global stent trial to test Xience against coronary bypass surgery

Abbott launches global stent trial to test Xience against coronary bypass surgery

October 4, 2011 By MassDevice staff

Stent Wars

Abbott Laboratories’ (NYSE:ABT) enrolled the first patient in its global Excel trial, the largest clinical study to date examining surgical and stenting outcomes in patients with unprotected left main disease.

Abbott will compare its Xience Prime and Xience V everolimus-eluting stents against coronary artery bypass grafting in a multi-center, randomized prospective trial spanning more than 2,6000 patients and up to 165 medical centers in 18 countries.

Left main disease is a high-risk subset of coronary artery disease where a lesion blocks the left main artery in the heart. The standard treatment involves a surgical bypass and stenting is generally reserved for patients who are too sick to undergo surgery but are "protected" by a previous bypass graft.

"With the advancement of technology and expertise, coronary stenting might have potential as an alternative to coronary bypass surgery for select patients with left main disease," principal investigator Dr. Joseph Sabik said in prepared remarks.  

The first U.S. patient was enrolled at Turkey Creek Medical Center in Knoxville, Tenn.

Abbott’s Xience drug-eluting stents got a leg up over competing stents by Boston Scientific Corp. (NYSE:BSX) when researchers found that an everolimus coating is better than stents coated in other drugs at reducing thrombosis risk without increasing the risk of target vessel revascularization or heart attack

Boston Scientific’s Taxus stents are coated in paclitaxel.

Abbott’s Xience V bested Boston Scientific’s Taxus in another recent study showing that it reduced the risks for death, heart attack, stent thrombosis and recurrent ischemia in nondiabetic patients, compared to Taxus. The latest study adds to a pile of Abbott releases touting Xience V’s merits over Taxus.

Luckily for BSX, it’s still the top dog in the $4.6 billion U.S. DES market, posting $1.5 billion in sales and a 33 percent market share in the U.S. in 2010; Abbott followed in second place with $1.4 billion and a 31 percent share. And Boston Scientific has its own everolimus-eluting stent, the Promus, which won FDA clearance in May.

Filed Under: News Well, Research & Development Tagged With: Abbott, Boston Scientific, Clinical Trials, Stent Wars

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy